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Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on
breast cancer excision whole sections: an international multicentre collaboration
Aims: The nuclear proliferation marker Ki67 assayed
by immunohistochemistry has multiple potential uses
in breast cancer, but an unacceptable level of inter-
laboratory variability has hampered its clinical utility.
The International Ki67 in Breast Cancer Working
Group has undertaken a systematic programme to
determine whether Ki67 measurement can be analyt-
ically validated and standardised among laboratories.
This study addresses whether acceptable scoring
reproducibility can be achieved on excision whole
sections.
Methods and results: Adjacent sections from 30 pri-
mary ER+ breast cancers were centrally stained for
Ki67 and sections were circulated among 23 patholo-
gists in 12 countries. All pathologists scored Ki67 by
two methods: (i) global: four fields of 100 tumour
cells each were selected to reflect observed hetero-
geneity in nuclear staining; (ii) hot-spot: the field
with highest apparent Ki67 index was selected and
up to 500 cells scored. The intraclass correlation
coefficient (ICC) for the global method [confidence
interval (CI) = 0.87; 95% CI = 0.799–0.93] margin-
ally met the prespecified success criterion (lower 95%
CI ≥ 0.8), while the ICC for the hot-spot method
(0.83; 95% CI = 0.74–0.90) did not. Visually, inter-
observer concordance in location of selected hot-spots
varies between cases. The median times for scoring
were 9 and 6 min for global and hot-spot methods,
respectively.
Conclusions: The global scoring method demonstrates
adequate reproducibility to warrant next steps
towards evaluation for technical and clinical validity
in appropriate cohorts of cases. The time taken for
scoring by either method is practical using counting
software we are making publicly available. Establish-
ment of external quality assessment schemes is likely
to improve the reproducibility between laboratories
further.
Keywords: analytical validity, immunohistochemistry, interobserver reproducibility, interobserver variability,
Ki67, pathology, scoring protocol
Introduction
The nuclear antigen recognised by the Ki67 antibody is
expressed in proliferating cells but absent in resting
cells.1 Since its discovery in 1983 by Gerdes et al.,1 Ki67
assessed by immunostaining has been studied exten-
sively as a prognostic2–11 and predictive4,6,9,12,13 mar-
ker, predominantly in hormone receptor-positive breast
cancer, but also in other tumours.14–18 For example,
presurgical Ki67 has been shown to be a marker for
recurrence-free survival19 and, in the neoadjuvant set-
ting, a marker for endocrine-resistant tumour that may
require more aggressive treatment.20 Excellent intra-ob-
server reproducibility under controlled pre-analytical
and staining conditions21 has contributed to the body of
evidence showing the potential of Ki67 immunohisto-
chemistry assay to be implemented in hospital laborato-
ries as a cost-effective part of clinical management.22–24
However, poor interobserver reproducibility and vari-
ability due to technical aspects of the assay has limited
its adoption in clinical practice.4,9,25–28
The International Ki67 Working Group (IKWG)
has undertaken a systematic multiphase programme
to determine whether Ki67 scoring can be standard-
ised and analytically validated throughout
laboratories.9,21,29,30 In Phase I, as assessed by the intr-
aclass correlation coefficient (ICC) estimate of interob-
server reproducibility, differences in pathologists’ visual
interpretation were the main source of variability
(ICC = 0.71, 95% credible interval (CI) = 0.47–0.78).21
Greater concordance was achieved in Phase II, at least
on tissue microarrays, when pathologists were trained
to calibrate and standardise scoring according to a
clearly defined methodology (ICC = 0.94, 95%
CI = 0.90–0.97).29 However, in clinical practice, deci-
sions are made on core-cut biopsy or excision speci-
mens, which require general assessment of the entire
sample and selection of areas for formal counting.
Therefore, in Phase IIIA, we assessed whether accept-
able performance could be achieved on core-cut biopsies
using a standardised method with two distinct methods
of scoring field selection: global (four representative
fields, counting 100 nuclei each) and hot-spot (one field
with highest Ki67, counting 500 nuclei). The global
method achieved acceptable interobserver reproducibil-
ity (ICC = 0.87; 95% CI = 0.81–0.93) according to our
prespecified criteria, whereas the hot-spot method did
not (ICC = 0.84; CI = 0.77–0.92).30
The current study represents the final Phase (IIIB)
of the visual scoring analytical validity programme,
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wherein we assess whether acceptable performance
can be achieved on centrally stained excision whole
sections using the scoring method established on
core-cut biopsies. Future studies will be required to
evaluate variability due to staining and pre-analytical
aspects of the assay.
Materials and methods
This study was approved by the British Columbia Can-
cer Agency Clinical Research Ethics Board (H10-
03420). All specimens used in this study were donated
by patients who signed institutionally appropriate con-
sent forms, were excess to diagnostic requirements,
and ethically available for quality control studies.
C A S E S E L E C T I O N A N D S A M P L E P R E P A R A T I O N
Excision blocks from 30 oestrogen receptor (ER)-posi-
tive breast cancer cases were selected: 15 from the
Phase IIIA study30 and 15 from Kawasaki Medical
School Hospital, Kurashiki, Japan (Figure S1). Case
selection was irrespective of patients’ age at diagnosis,
tumour grade, size or nodal status. The clinicopatho-
logical characteristics of these 30 cases are shown in
Table S1. All blocks were sectioned and stained in
the Royal Marsden Hospital Histopathology Depart-
ment using monoclonal antibody MIB1 at dilution
1:50 (Dako UK, Ely, UK) using an automated staining
system (Ventana Medical Systems, Tucson, AZ, USA)
according to criteria established by the IKWG.9 Sec-
tions from the same block were stained in a single
immunohistochemistry run, except for four cases
where the staining was performed in two different
runs. This approach effectively controls for any tech-
nical variation in staining.
S A M P L E D I S T R I B U T I O N
Twenty-four volunteer pathologists representing 24
institutions from 12 countries, most of whom partici-
pated in the Phase IIIA study, were invited to partici-
pate.
Six adjacent sections from each of the 30 excision
blocks were centrally stained: the first with haema-
toxylin and eosin (H&E), the second with p63 (my-
oepithelial marker, to assist the identification of
invasive foci) and the third to sixth with Ki67 (desig-
nated as slide sets 1–4). To facilitate application to
the general histopathology laboratory environment,
physical glass slides (as opposed to virtual slide
images) were distributed to the volunteer
pathologists. Because the accumulated delays
required would have made the study impractical if all
pathologists reviewed the same physical glass slides,
participating pathologists were divided into four
groups and were given one of the four sets of Ki67
slides to score. The H&E and p63 reference slides
were made available online as digital images.
Twenty-three pathologists successfully completed the
study.
S C O R I N G P R O T O C O L
All pathologists were specifically trained to score Ki67
with emphasis on having a very low threshold for
appreciating ‘brown stain’ and the principles of stan-
dardised regions for nuclei counting, through the pub-
licly available proficiency training module (http://
www.gpec.ubc.ca/calibrator) that was initially used in
the Phase II study.29 The detailed scoring protocol is
found in Data S1. A modified version of the scoring soft-
ware used in this study is available freely from the Goo-
gle Play and Apple iTunes store (search term: ‘Ki67’).
S C O R I N G M E T H O D S
The scoring methods used were the same as those
employed in the Phase IIIA study30: (i) a global
assessment that is weighted according to the esti-
mated percentage of the total cancer area covered by
each of high, medium, low or negligible Ki67 staining
levels; (ii) an unweighted global assessment; and (iii)
assessment of Ki67 only in a ‘hot-spot’ area.
Global methods attempt to derive an average score
across all the tissue available for assessment. In the
weighted and unweighted global methods, Ki67 index
counting was performed in the same fashion, but the
final Ki67 score was derived differently. Adapted from a
scoring protocol that has been used routinely in the
Dowsett laboratory,31 these two global methods require
the pathologist to first assess staining heterogeneity by
estimating the percentages of the invasive tumour com-
ponent of the slide exhibiting relatively high, medium,
low or negligible Ki67 staining frequencies. Based on
these estimates, an algorithm (Figure S2) dictates the
required number of fields to select and score for each
Ki67 staining frequency (irrespective of staining inten-
sity, totalling up to four fields). This algorithm was
designed such that the four (or fewer) selected scoring
fields would capture the full range of staining frequen-
cies, while at the same time be reflective of the propor-
tion in staining frequencies heterogeneity. Up to 100
invasive tumour nuclei within each field are counted
using a ‘typewriter’ pattern (Figure S3), similar to how
© 2019 John Wiley & Sons Ltd, Histopathology, 75, 225–235.
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a tissue microarray core was scored in the Phase II
study.29
The hot-spot method requires the pathologist to
visually select one high-power field with the highest
apparent staining rate and, within that area only,
count up to 500 invasive tumour nuclei in a ‘type-
writer’ pattern.
S T A T I S T I C A L A N A L Y S E S
Prespecified criterion for success
Prior to data collection it was hypothesised that at
least one of the scoring methods would have an asso-
ciated ICC statistically greater than 0.80 (ICC of 0.8
being considered as good concordance32). For plan-
ning purposes, power calculations performed under a
variety of scenarios considered to represent good
reproducibility (and similar to the results observed in
the Phase II study) showed that with at least 21 par-
ticipating pathologists scoring 30 cases, there would
be 80% power to exclude ICCs lower than the pre-
specified ICC of 0.8 from a 95% credible interval for a
given scoring method.
Ki67 score
The Ki67 score was defined as in the Phase IIIA study.30
Positive staining was defined as any brown stain in the
nucleus above background, with reference available as
needed to provide standard sample images; negative
staining was scored when an invasive cancer cell
showed only a blue counterstained nucleus. The
unweighted global and hot-spot scores were simply the
total number of positively stained tumour nuclei
counted divided by the total number of tumour nuclei
counted. The weighted global score was derived with
tumour nuclei counts in each assessed field weighted by
the estimated percentage of the total cancer area cov-
ered by each of high, medium, low or negligible Ki67
staining levels. As in our previous studies, to satisfy
model assumptions of normality and constant variance,
for statistical analyses the Ki67 score is converted to a
logarithmic scale by adding 0.1% and applying a log
base 2 transformation.
ICC estimates (ranging from 0 to 1, with 1 repre-
senting perfect reproducibility) were computed as pre-
viously reported in the Phase IIIA study.30 Briefly,
variance component analyses were performed to
quantify the contributions from the following sources
of variability: scoring pathologist (observer), patient
tumour (biological variation – each excision block
represents a unique patient) and section of the exci-
sion block. Similar to the Phase IIIA study, same-sec-
tion and different-section ICCs were computed. Same-
section refers to pathologists scoring the same exci-
sion whole section physical slides, while different-sec-
tion refers to pathologists scoring different physical
slides that represent serial sections cut from the same
original excision blocks. Credible intervals for the
variance components and the ICCs were obtained
using the Markov Chain Monte Carlo routines for fit-
ting generalised linear mixed models.
All data analyses were performed using R version
3.3.2.33 Sources of variation in log2-transformed
Ki67 scores were analysed using random effects mod-
els as implemented in the R packages lme4 and
MCMCglmm. Data were visualised using heat maps,
box-plots and spaghetti plots.
Results
I C C O F K I 6 7 A C C O R D I N G T O S C O R I N G M E T H O D
The different-section ICC estimate for the weighted
global scores was 0.87 (95% CI = 0.799–0.93), at
the margin of the prespecified success criterion (lower
bound of credible interval exceeding 0.8) (Table 1).
The different-section ICCs for the unweighted global
scores and hot-spot scores were 0.86 (95%
CI = 0.793–0.92) and 0.83 (95% CI = 0.74–0.90),
respectively, and therefore both these methods had
ICC credible intervals that extended below the success
criterion at the lower 95% limit. The corresponding
same-section ICC estimates for the weighted global,
unweighted global and hot-spot scores were virtually
identical 0.87 (95% CI = 0.799–0.92), 0.86 (95%
CI = 0.79–0.92) and 0.83 (95% CI = 0.74–0.90)
Table 1. Summary of ICC values for different scoring methods
Different-section ICC Same-section ICC
Weighted global 0.87 (95% CI = 0.799–0.93) 0.87 (95% CI = 0.799–0.92)
Unweighted global 0.86 (95% CI = 0.79–0.92) 0.86 (95% CI = 0.79–0.92)
Hot-spot 0.83 (95 % CI = 0.74–0.90) 0.83 (95% CI = 0.74–0.90)
ICC, Intraclass correlation coefficient; CI, Confidence interval.
© 2019 John Wiley & Sons Ltd, Histopathology, 75, 225–235.
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respectively, supporting that differences between
serial sections were minimal. Figure 1 displays the
side-by-side box-plots of Ki67 scores among patholo-
gists (hereafter referred to as ‘observers’) by group.
Summary statistics for the Ki67 scores among the 23
observers are given in Tables S2–S4.
The median number of nuclei counted per slide
(across all observers and cases) was 400 and 500 for
the global and hot-spot methods, respectively. The
corresponding minimum number of nuclei counted
was 300 and 138. Eighteen per cent of the hot-spot
scores were based on <500 nuclei counts. Among
these 126 hot-spot scores, the median number of
nuclei counted was 375.
In a context where pre-analytical and staining fac-
tors are held constant, variance component analyses
show that, regardless of scoring method, biological
variation among different patients was the largest com-
ponent of the total variation on these centrally stained
slides, indicating that the Ki67 score is reflecting inher-
ent properties of the tumour (Figure 2, Table S5).
I N T E R O B S E R V E R V A R I A T I O N O F K I 6 7 S C O R I N G
Figure 3 displays the variation in scores across obser-
vers for cases in slide set 1 as spaghetti plots. The
corresponding plots for slide sets 2–4 are displayed in
Figure S4. Figure 4 presents the scores in a heat-map
format with the columns (observers) ordered (within
each slide set) by the median scores across cases and
the rows (cases) sorted by the median scores across
observers.
Overall, it can be seen that most observers show
good parallelism in the increasing Ki67 scores
throughout the plots. In other words, observers mea-
suring higher or lower than others tended to do so
relatively consistently.
C A T E G O R I C A L C O N C O R D A N C E O F K I 6 7 S C O R I N G
Regarding concordance on a categorical level (<10,
10–20 and >20%), the relationship between concor-
dance and continuous score is shown in Figure S5. It
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Figure 1. Ki67 scores of all 23 observers (by slide set). Observers are ordered (within each group) by the median scores. The bottom/top of
the box in each box plot represent the first (Q1)/third (Q3) quartiles, the bold line inside the box represents the median and the two bars
outside the box represent the lowest/highest datum still within 1.59 the interquartile range (Q3–Q1). Outliers are represented with empty
circles.
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shows excellent to perfect concordance on cases with
scores that are either much lower or higher than the
intermediate range (10–20%).
Based on visual inspection of captured images, loca-
tions of the hot-spot selections tended to cluster in the
same region among observers within each of the exci-
sion whole-section slides (Figure 5 shows some exam-
ples; virtual slide images of all slides used in this study
and the corresponding selected fields and scores can be
viewed at http://www.gpec.ubc.ca/papers/ki67p3b).
Variance component analysis
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Weighted global score
Unweighted global score
Hot-spot score
Component
Va
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0
Figure 2. Variance component
analysis. Variation due to
different components are
presented in a bar plot to show
the relative magnitude of
differences between them.
Numerical values of the
variance components estimates
and the corresponding credible
intervals are shown in
Table S5.
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Figure 4. Heat-map of Ki67
scores (A, weighted global; B,
unweighted global; C, hot-
spot). Rows represent cases
and columns represent
observers. Green colour
indicates that the score is
<10%, yellow 10–20% and red
>20%. Cases are ordered by
the median scores (across
observers), which are shown in
parentheses beside the
specimen number. Observers
are ordered (within each
group) by the median scores
(across cases). The three colon-
separated numbers to the right
of the heat-map represent the
number of observers giving
scores falling into different
ranges: <10% (left), 10–20%
(middle) and >20% (right). For
example, ‘15:6:1’ indicates
that 15 observers gave a score
of <10%, six observers between
10% and 20% and one
observer >20%.
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The median scoring time (field selection and
nuclear counting) was 9 (interquartile range: 7–11)
and 6 (interquartile range = 4–8) minutes for global
and hot-spot methods, respectively.
Discussion
The IKWG has demonstrated that it is possible, when
controlling stringently for variability due to pre-
A
Bi
10 mm 20 mm
20 mm
6 mm
M:16.2%
J:23.6%D:5.6%
20 mm
Bii
BivBv
Biii
Figure 5. Hot-spot field selection by different observers on the same excision whole section slide. A, Selections (indicated by red circles) on
some example excision whole section slides. B, An example of a single excision whole section slide (median score: 18%) with zoomed-in
fields. Each observer was asked to circle the area considered to be the hot-spot (B-i). Most observers honed in on the same general area of
the slide, although individual selected scoring fields do not always overlap. B-iii and B-iv represent segments of the same area chosen by two
different observers to read Ki67. Figure B-v represents the ‘outlier’ field selected by only one observer as the hot-spot.
© 2019 John Wiley & Sons Ltd, Histopathology, 75, 225–235.
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analytical and analytical aspects of the Ki67
immunohistochemistry assay,9 and given a set of
clearly defined training exercise and scoring instruc-
tions, for pathologists to achieve high interobserver
concordance in Ki67 scoring on core-cut biopsies and
now on excision whole sections using a conventional
light microscope and manual field selection, with no
additional aid such as a counting grid.
Due to the limited sample size, we were unable to
assess whether any specific method (weighted global,
unweighted global or hot-spot) is significantly more
reproducible than others. However, the observed ICCs
for global score (weighted = 0.87; unweighted = 0.86)
are relatively higher compared to hot-spot score (0.83),
suggesting that a sufficiently powered study might be
able to show more convincingly whether global scores
are more reproducible. This result is consistent with
findings on core biopsies.30
Can this level of concordance be clinically ade-
quate? The POETIC11 study assessed Ki67 (cut-point
at 10%) as a prognostic marker. Applying this cut-
point to the data in our current study, 17 (of 30)
cases have, at most, one discordance in weighted glo-
bal score (Figure 4A). There are cases with major dis-
crepancies: TB036, on the same physical slide (set 2),
received a weighted global score of 4 and of 21%
from observers A and L, respectively. However, it is
apparent (Figure 4) that cases far away from the
intermediate range (10–20%) tend to have good
agreement. Considering that cases in our current
study are a random sampling of the general ER+
breast cancer population, one could expect that
approximately half of these cases would fall away
from the intermediate range, and hence Ki67 may
provide clinically adequate information, provided that
the staining and pre-analytical factors do not add too
much variability.
Are the proposed scoring methods practical? The
median scoring time is 6–9 min, depending on the
method used. However, an adaptive scoring protocol
can be used to reduce scoring time if the purpose is
to assess whether Ki67 is above or below a specific
cut-point. For example, considering the global scoring
method, where the maximum nuclei count is prespec-
ified (i.e. 400), to determine whether a case has
unweighted global score ≥10% the pathologist can
stop counting if the first field they scored is ≥40%.
For cases with a very low Ki67 score, one would
probably still need to count all 400 nuclei.
The proposed scoring protocols do not make any
recommendation concerning the required minimum
tumour nuclei count. This is a limitation of this study
and, in practice, it will be up to the discretion of the
scoring pathologist to assess if too few tumour nuclei
are available for an adequate Ki67 assessment. This
will depend on the percentage of positive cells scored
in the cells available and the clinical context for the
measurement.
An external quality assessment programme (e.g.
NordiQC34), involving comparison of laboratory
scores with reference scores in periodic assessment
challenges, will probably improve interobserver repro-
ducibility further. Recent studies suggest that an even
higher level of concordance can be achieved with
automated image analysis.35–38 The IKWG is actively
conducting studies in this area to assess how artificial
intelligence may help to standardise Ki67 assess-
ment.35,38 Also, concordance between Ki67 scores on
core biopsies and excision specimens is currently
being investigated.
In conclusion, this study demonstrates that an ade-
quately high level of interobserver concordance can
be achieved by visual assessment of Ki67 using prac-
tical scoring methods, although some cases with large
discrepancies remain. A two-tier assessment approach
may be worthy of further study as a means to reduce
scoring burden and further address challenging cases:
if the Ki67 value from the initial scoring falls on a
grey zone (e.g. cut-point  5%), scoring by a second
pathologist or alternative test could be pursued. Pre-
analytical and analytical aspects of the immunohisto-
chemistry assay, areas that still need standardisation
before the clinical utility of this marker can be
proved, will probably add more variability. A clinical
validation study employing analytically reproducible
methodology would also need to be completed in
appropriate cohorts of cases to determine whether
Ki67 can be recommended for patient care decisions.
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